Holmes Joseph R. 4
4 · THERMO FISHER SCIENTIFIC INC. · Filed Feb 27, 2026
Research Summary
AI-generated summary of this filing
Thermo Fisher (TMO) VP Joseph R. Holmes Receives Stock Awards
What Happened
Joseph R. Holmes, Vice President & Chief Accounting Officer of Thermo Fisher Scientific (TMO), was awarded a total of 1,755 equity units on February 25, 2026. The filing shows three acquisitions at $0.00: 433 shares (performance-based RSUs), 337 shares (adjustment to a prior performance RSU tranche), and 985 units reported as a derivative (an option award). The Form 4 reports $0.00 as the acquisition price (typical for RSU/option grants); no immediate cash transaction was reported.
Key Details
- Transaction date: February 25, 2026. Form filed: February 27, 2026 (timely).
- Reported acquisitions: 433 shares @ $0.00 (F1); 337 shares @ $0.00 (F2); 985 units @ $0.00 (derivative, F3). Total = 1,755 units.
- Footnote highlights:
- F1: 433 RSUs granted Feb 19, 2025; Compensation Committee certified performance on Feb 25, 2026. One‑third vests Feb 28, 2026 and 2027; final third vests Feb 28, 2028 and is subject to positive/negative adjustment tied to relative TSR vs. peers over 1/1/2025–12/31/2027.
- F2: 337 shares are an adjustment to a Feb 22, 2023 performance RSU; Committee certified a 15% reduction for relative TSR, which equals 6 fewer shares than previously reported.
- F3: The 985-unit derivative appears to be an option that vests in four equal annual installments beginning Feb 28, 2027.
- Shares owned after the reported transactions: not specified in the filing.
- Exhibit listed: Exhibit 24 — Power of Attorney.
Context
These are compensation awards (performance-based RSUs and an option-style award), not open-market purchases or sales. RSUs convert to shares only upon vesting and performance certification; the derivative award vests over future years. Such grants are a routine part of executive compensation and do not by themselves indicate a buy/sell decision by the insider.
Insider Transaction Report
- Award
Common Stock
[F1][F2]2026-02-25+433→ 2,745.982 total - Award
Common Stock
2026-02-25+337→ 3,082.982 total - Award
Stock Option (Right to Buy)
[F3]2026-02-25+985→ 985 totalExercise: $513.68Exp: 2036-02-25→ Common Stock (985 underlying)
Footnotes (3)
- [F1]Shares represent a performance-based restricted stock unit award granted on February 19, 2025. The Company's Compensation Committee determined on February 25, 2026, that the performance criteria related to this award were satisfied. One-third of the shares vest on February 28, 2026 and 2027. The remaining one-third will vest on February 28, 2028, and is subject to adjustment (positive or negative) for long-term performance which is based on the comparison of the Company's total shareholder return compound annual growth rate ("CAGR") to the total shareholder return CAGR of each of the companies in the peer group, as specified within the award agreement, over the measurement period starting on January 1, 2025, through to December 31, 2027.
- [F2]Shares represent an adjustment to the final tranche of a performance-based restricted stock unit award granted on February 22, 2023. On February 25, 2026, the Compensation Committee certified a 15% reduction based on the Company's relative TSR performance over the three-year measurement period, resulting in 6 fewer shares than previously reported.
- [F3]The option vests in four equal annual installments beginning on February 28, 2027.